AU1927992A - Medicaments - Google Patents

Medicaments

Info

Publication number
AU1927992A
AU1927992A AU19279/92A AU1927992A AU1927992A AU 1927992 A AU1927992 A AU 1927992A AU 19279/92 A AU19279/92 A AU 19279/92A AU 1927992 A AU1927992 A AU 1927992A AU 1927992 A AU1927992 A AU 1927992A
Authority
AU
Australia
Prior art keywords
tetrahydro
benzazepine
hydroxy
compound
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19279/92A
Other languages
English (en)
Inventor
Alberto Julio Kaumann
John Gerard Ward
Rodney Christopher Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919113379A external-priority patent/GB9113379D0/en
Priority claimed from GB919113377A external-priority patent/GB9113377D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU1927992A publication Critical patent/AU1927992A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU19279/92A 1991-06-21 1992-06-17 Medicaments Abandoned AU1927992A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9113377 1991-06-21
GB919113379A GB9113379D0 (en) 1991-06-21 1991-06-21 Medicaments
GB919113377A GB9113377D0 (en) 1991-06-21 1991-06-21 Medicaments
GB9113379 1991-06-21

Publications (1)

Publication Number Publication Date
AU1927992A true AU1927992A (en) 1993-01-25

Family

ID=26299102

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19279/92A Abandoned AU1927992A (en) 1991-06-21 1992-06-17 Medicaments

Country Status (9)

Country Link
EP (1) EP0589973A1 (pt)
JP (1) JPH06508352A (pt)
KR (1) KR940701258A (pt)
AU (1) AU1927992A (pt)
CA (1) CA2110575A1 (pt)
IE (1) IE921990A1 (pt)
MX (1) MX9203012A (pt)
PT (1) PT100602A (pt)
WO (1) WO1993000094A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
JP2001508759A (ja) * 1996-03-25 2001-07-03 イーライ・リリー・アンド・カンパニー 片頭痛の処置法
JPWO2002074746A1 (ja) * 2001-03-16 2004-07-08 山之内製薬株式会社 ベンゾアゼピン誘導体
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
MXPA05006567A (es) 2002-12-20 2005-08-16 Glaxo Group Ltd Derivados de benzazepina para el tratamiento de trastornos neurologicos.
CN101792417A (zh) 2003-06-17 2010-08-04 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
EP2189448B1 (en) 2003-06-17 2014-01-29 Arena Pharmaceuticals, Inc. Processes for the Separation of 3-Benzazepine Racemates
TW200510324A (en) * 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
KR101281919B1 (ko) 2004-12-21 2013-07-03 아레나 파마슈티칼스, 인크. (ｒ)-8-클로로-1-메틸-2,3,4,5-테트라히드로-1ｈ-3-벤즈아제핀 히드로클로라이드의 결정질 형태
PT1833473E (pt) 2004-12-23 2009-12-17 Arena Pharm Inc Composições de modulador de receptor 5ht2c e métodos de utilização
EP2001852A2 (en) 2006-04-03 2008-12-17 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
CA2670285A1 (en) 2006-12-05 2008-06-12 Arena Pharmaceuticals, Inc. Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
JP5491421B2 (ja) 2008-03-04 2014-05-14 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストである（ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンに関連する中間体の調製のためのプロセス
CN102648170A (zh) 2009-06-18 2012-08-22 艾尼纳制药公司 制备5-ht2c受体激动剂的方法
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
MX2013002430A (es) * 2010-09-01 2013-07-22 Arena Pharm Inc Formas de dosis de disolucion de rápida de agonistas de 5-ht2c.
EP2939677A1 (en) 2010-09-01 2015-11-04 Arena Pharmaceuticals, Inc. Administration of lorcaserin to indviduals with renal impairment
ES2704455T3 (es) 2010-09-01 2019-03-18 Arena Pharm Inc Formas farmacéuticas de liberación modificada de agonistas de 5-HT2C útiles para la gestión del peso
CN103189360A (zh) 2010-09-01 2013-07-03 艾尼纳制药公司 5-ht2c激动剂的非吸湿性盐
WO2012030938A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
AU2012392187B2 (en) 2012-10-09 2018-07-12 Arena Pharmaceuticals, Inc. Method of weight management

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659706A (en) * 1985-12-20 1987-04-21 Smithkline Beckman Corporation Sulfinyl and sulfonyl substituted 3-benzazepines

Also Published As

Publication number Publication date
MX9203012A (es) 1993-07-01
IE921990A1 (en) 1992-12-30
PT100602A (pt) 1993-09-30
WO1993000094A3 (en) 1993-03-04
CA2110575A1 (en) 1993-01-07
JPH06508352A (ja) 1994-09-22
WO1993000094A2 (en) 1993-01-07
KR940701258A (ko) 1994-05-28
EP0589973A1 (en) 1994-04-06

Similar Documents

Publication Publication Date Title
AU1927992A (en) Medicaments
AU2002228007B8 (en) Indole derivatives and their use as 5-HT2b and 5-HT2c receptor ligands
US20030018043A1 (en) Compositions and methods for treating opiate intolerance
KR910000251B1 (ko) 비시클로 치환된 페닐아세토니트릴 유도체
CZ149898A3 (cs) Použití epinastinu pro výrobu farmaceutického prostředku
AU2014323822B2 (en) Immune adjustment compound, use thereof and pharmaceutical composition comprising same
WO1999020620A1 (fr) Derive d'isoquinoleine et medicament
WO2000028993A1 (en) Serotonin ligands as pro-erectile compounds
EP0771563B1 (en) Use of 5-HT1A receptor ligands for the treatment of glaucoma
JP2502343B2 (ja) 薬学的に活性な置換ベンズアミド
PT644878E (pt) Compostos 2,5-dio-2,5-di-hidro-1h-benzo¬b|azepina como antagonistas do receptor nmda
CN114149423A (zh) 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
JPWO2005079845A1 (ja) 片頭痛予防薬
EP0238281B1 (en) Selective alpha-adrenergic receptor antagonists
CN114456163A (zh) 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
JP2010501557A (ja) 血液脳関門を通過しないｋｗ−３９０２コンジュゲート
EA007952B1 (ru) Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии
Frishman et al. Beta-adrenergic blockade: an update
JPH02229167A (ja) プロドラッグとしての６―クロロ―７，８―ジヒドロキシ―１―（４’―ヒドロキシフェニル）―２，３，４，５―テトラヒドロ―１ｈ―３―ベンズアゼピンのカルバメート
CA2153083A1 (en) Pharmaceutical compositions and a process for the preparation thereof
KR20020012314A (ko) 빈뇨 혹은 요실금의 치료 또는 예방제
EP0382618A2 (fr) Dérivés aminoalkoxyphényle, leur procédé de préparation ainsi que les compositions en contenant
JP2001199884A (ja) 鎮痛作用剤
EP0382628A1 (fr) Dérivés aminoalkoxyphényle, leur procédé de préparation ainsi que les compositions en contenant
JPH05501711A (ja) ムスカリン性受容体拮抗剤